Pixium Vision: Annual General Meeting and Board of Directors of June 27, 2018

PARIS--()--Regulatory News:

The Annual General Meeting of Pixium Vision (Paris:PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, was held in Paris on June 27, 2018 and adopted all the proposed resolutions.

The Annual General Meeting has, in particular, renewed for 3 years the terms of office of Mr James Reinstein, independent Director, and the company BPIfrance Participations, represented by Mrs Olivia Le Proux de la Rivière. The Annual General Meeting has also appointed Mrs Marie Meynadier as independent Director for a term of 3 years.

We are very pleased to have Marie join our board and look forward to her contributions.” said Bernard Gilly, Chairman of the Board of Pixium Vision. “Marie is a French leader in the medical technology industry and she understands the power we have to innovate in our sector. Her experience as an entrepreneur, an engineer, and an industry disruptor will be invaluable to Pixium to grow as the leading company in retinal implant.”

The Board of Directors of Pixium Vision is now composed of the following members:

  • Mr Bernard Gilly, Chairman of the Board
  • Mr Khalid Ishaque, Chief Executive Officer
  • BPIfrance Participations, represented by Mrs Olivia Le Proux de la Rivière, Director
  • BPIfrance Investissement, represented by Mrs Chahra Louafi, Director
  • Mrs Marie Meynadier, Independent Director
  • Mr. James Reinstein, Independent Director
  • Robert J. W. Ten Hoedt, Independent Director
  • Sofinnova Partners, represented by Mr Antoine Papiernik, Observer
  • Mr Timothy J. Haines, Observer
  • Kreos Capital V (Expert Fund) LTD, represented by Mr Aris Constantidines, Observer

ABOUT PIXIUM VISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision is now conducting a clinical study1 in Human with PRIMA, its new generation sub-retinal miniaturized photovoltaic wireless implant system, for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Stanford University in California, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” par Bpifrance.

For more information, please visit: www.pixium-vision.com;
And follow us on: Twitter: @PixiumVision; Facebook: www.facebook.com/pixiumvision
LinkedIn: www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF on March 26, 2018 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).
IRIS® is a trademark of Pixium-Vision SA

Contacts

Contacts
Pixium Vision
Didier Laurens, CFO
investors@pixium-vision.com
+33 1 76 21 47 68
@PixiumVision
or
Media Relations
Newcap Media
Annie-Florence Loyer - afloyer@newcap.fr
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin - ljacquin@newcap.fr
+33 1 44 71 94 94

Contacts

Contacts
Pixium Vision
Didier Laurens, CFO
investors@pixium-vision.com
+33 1 76 21 47 68
@PixiumVision
or
Media Relations
Newcap Media
Annie-Florence Loyer - afloyer@newcap.fr
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin - ljacquin@newcap.fr
+33 1 44 71 94 94